Zacks: Brokerages Expect CRISPR Therapeutics AG (NASDAQ:CRSP) Will Post Quarterly Sales of $4.99 Million

Tuesday, April 6, 2021 | MarketBeat

Wall Street analysts expect CRISPR Therapeutics AG (NASDAQ:CRSP) to post $4.99 million in sales for the current quarter, according to Zacks Investment Research. Three analysts have made estimates for CRISPR Therapeutics' earnings, with the highest sales estimate coming in at $13.70 million and the lowest estimate coming in at $400,000.00. CRISPR Therapeutics reported sales of $160,000.00 in the same quarter last year, which indicates a positive year over year growth rate of 3,018.8%. The firm is scheduled to announce its next earnings report on Tuesday, April 27th.

On average, analysts expect that CRISPR Therapeutics will report full year sales of $28.35 million for the current year, with estimates ranging from $1.60 million to $90.00 million. For the next year, analysts expect that the business will report sales of $66.74 million, with estimates ranging from $3.50 million to $153.50 million. Zacks' sales averages are a mean average based on a survey of research analysts that cover CRISPR Therapeutics.

CRISPR Therapeutics (NASDAQ:CRSP) last released its quarterly earnings results on Monday, February 15th. The company reported ($1.50) EPS for the quarter, missing analysts' consensus estimates of ($1.27) by ($0.23). The company had revenue of $0.37 million during the quarter, compared to analysts' expectations of $4.69 million. CRISPR Therapeutics had a negative net margin of 273.10% and a negative return on equity of 20.72%.

CRSP has been the topic of several analyst reports. Barclays boosted their price target on shares of CRISPR Therapeutics from $113.00 to $140.00 and gave the stock an "overweight" rating in a report on Monday, March 8th. The Goldman Sachs Group reduced their target price on CRISPR Therapeutics from $193.00 to $189.00 and set a "neutral" rating for the company in a report on Wednesday, February 17th. Wells Fargo & Company lowered CRISPR Therapeutics from an "overweight" rating to an "equal weight" rating and lifted their price target for the stock from $102.63 to $145.00 in a report on Monday, December 7th. JMP Securities initiated coverage on CRISPR Therapeutics in a research report on Wednesday, March 10th. They issued an "outperform" rating and a $160.00 price objective on the stock. Finally, Zacks Investment Research lowered CRISPR Therapeutics from a "hold" rating to a "sell" rating and set a $177.00 target price for the company. in a research report on Monday, February 1st. Three equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and twelve have issued a buy rating to the company's stock. The company currently has an average rating of "Hold" and a consensus target price of $159.94.

Shares of CRSP stock opened at $121.99 on Tuesday. The firm has a 50-day moving average of $128.34 and a 200-day moving average of $131.84. CRISPR Therapeutics has a one year low of $39.25 and a one year high of $220.20. The company has a market cap of $9.20 billion, a P/E ratio of -37.42 and a beta of 2.37.

In other CRISPR Therapeutics news, General Counsel James R. Kasinger sold 27,500 shares of CRISPR Therapeutics stock in a transaction dated Tuesday, January 19th. The stock was sold at an average price of $204.94, for a total transaction of $5,635,850.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Bradley J. Phd Bolzon sold 30,374 shares of the company's stock in a transaction dated Monday, March 22nd. The shares were sold at an average price of $132.37, for a total value of $4,020,606.38. Following the sale, the director now owns 57,149 shares in the company, valued at $7,564,813.13. The disclosure for this sale can be found here. Insiders have sold a total of 102,874 shares of company stock worth $19,309,856 over the last 90 days. 17.10% of the stock is currently owned by corporate insiders.

A number of large investors have recently modified their holdings of CRSP. Trustcore Financial Services LLC purchased a new stake in CRISPR Therapeutics in the 4th quarter worth approximately $31,000. Parallel Advisors LLC bought a new stake in CRISPR Therapeutics during the fourth quarter valued at $38,000. Capital Advisory Group Advisory Services LLC grew its position in CRISPR Therapeutics by 300.0% during the fourth quarter. Capital Advisory Group Advisory Services LLC now owns 248 shares of the company's stock worth $38,000 after buying an additional 186 shares in the last quarter. Gemmer Asset Management LLC grew its position in CRISPR Therapeutics by 438.0% during the fourth quarter. Gemmer Asset Management LLC now owns 269 shares of the company's stock worth $41,000 after buying an additional 219 shares in the last quarter. Finally, Huntington National Bank increased its stake in CRISPR Therapeutics by 45.0% in the 4th quarter. Huntington National Bank now owns 290 shares of the company's stock worth $44,000 after acquiring an additional 90 shares during the last quarter. 66.43% of the stock is owned by institutional investors.

About CRISPR Therapeutics

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for serious human diseases. The company develops its products using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), a gene editing technology that allows for precise directed changes to genomic DNA.

Further Reading: EV Stocks

Get a free copy of the Zacks research report on CRISPR Therapeutics (CRSP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for CRISPR Therapeutics (NASDAQ:CRSP)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]

Featured Article: How is inflation measured?



7 Cloud Computing Stocks to Lift Your Portfolio to New Heights

Cloud computing sounds complicated, and it has become more sophisticated as it evolves. However, the basic idea behind the cloud is the same. The “cloud” is a euphemistic term for the delivery of different services via the internet. In its early days, the cloud was used exclusively for data storage. Here’s an easy example of why this was important.

Back when the internet was cutting its teeth, I worked in marketing communications. The need to comply with Total Quality Control Systems (TQCS) for our largest clients meant we had to save every version of our files. Every. Single. One. Now imagine that you’re producing a 120-page product catalog complete with photos and charts. Your hard drive is burning up just thinking about it. Yet that “data” had to be stored somewhere. And so we had a virtual server farm to try to warehouse all these graphic intensive (and memory sucking) files until we could archive them.

Other than the storage nightmare, consider that it was a pain to work remotely. You could copy a file from the server, but then were you working on the right file? I’m sure at least one person is reading this who remembers this pain.

The cloud takes that away. Cloud computing allows you to store files on a secure, remote server that everyone can access anywhere they have an internet connection. But it’s become so much more than that. Cloud computing now gives businesses a platform from which they can create applications and software. If that sounds confusing, I hope to simplify it in this presentation. To help you understand which cloud computing stocks, you may want to add to your portfolio, and we’ve created this special presentation. These are seven of the cloud computing stocks that will continue to grow with the sector.

View the "7 Cloud Computing Stocks to Lift Your Portfolio to New Heights".


MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.